News & Events

Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing

Date:

May 31, 2019

Time:

8:00 a.m. – 6:00 p.m.

Location:

FDA’s White Oak Campus
Building 31, Room 1503 - Great Room
10903 New Hampshire Avenue
Silver Spring, Maryland 20993

FDA Campus Information (e.g., local airports, directions, and local hotels)

Registration:

Meeting Registration disclaimer icon

As stated in the Federal Register notice, requests to attend the hearing in person and/or present during the hearing must be received by May 10th. FDA will notify those who have been selected to present at the hearing by May 21st. Registering on this site to present does not guarantee a time slot. Space for in-person attendance at the hearing is limited. Registrants can also view the hearing via webcast.  All meeting attendees and other interested parties may submit information to the public docket FDA-2019-N-1482.

Background:

The Food and Drug Administration is announcing a public hearing to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. See the Federal Register notice for more information.

Webcast Information:

FDA will webcast this public hearing. Click here to view the hearing via webcast. Barring any technical difficulties, FDA plans to post a link to the recorded webcast after the hearing.

Submitting Comments:

FDA is establishing a docket for public comment on this hearing. The docket number is FDA-2019-N-1482. The docket will close on July 2, 2019. Submit either electronic or written comments on this public hearing by July 2, 2019. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before July 2, 2019. The Regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of July 2, 2019. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. Submit written comments to the Division of Docket’s Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852

Page Last Updated: 04/16/2019
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English